Overview

A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, 24-week study to evaluate the efficacy and safety of AXS-02 in subjects with knee osteoarthritis associated with bone marrow lesions.
Phase:
Phase 3
Details
Lead Sponsor:
Axsome Therapeutics, Inc.